ONO-2808 for Multiple System Atrophy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called ONO-2808 in patients with Multiple System Atrophy (MSA). The study aims to see if the drug is safe, how it behaves in the body, and whether it can improve symptoms of MSA. Researchers are comparing three different doses of ONO-2808.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. Please consult with the study team for guidance.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.
What safety data is available for ONO-2808 in treating Multiple System Atrophy?
Is the drug ONO-2808 a promising treatment for Multiple System Atrophy?
What makes the drug ONO-2808 unique for treating multiple system atrophy?
What data supports the idea that ONO-2808 for Multiple System Atrophy is an effective drug?
The available research does not provide specific data on the effectiveness of ONO-2808 for Multiple System Atrophy. The articles focus on other treatments, challenges in measuring outcomes, and the need for better clinical trials. There is no direct comparison or data on ONO-2808's effectiveness for this condition.611121314
Who Is on the Research Team?
Project Leader
Principal Investigator
Ono Pharmaceutical Co. Ltd
Are You a Good Fit for This Trial?
This trial is for patients with Multiple System Atrophy (MSA) who can walk unassisted, have had symptoms like Parkinsonism or ataxia for no more than 5 years, and are expected to live at least another 3 years. They must be able to swallow pills and not have other serious health issues or neurological disorders besides MSA.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple doses of ONO-2808 or placebo to assess safety, tolerability, pharmacokinetics, and pharmacodynamics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- ONO-2808
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ono Pharmaceutical Co. Ltd
Lead Sponsor
Shinji Takai
Ono Pharmaceutical Co. Ltd
Chief Medical Officer since 2023
MD from an unspecified institution
Gyo Sagara
Ono Pharmaceutical Co. Ltd
Chief Executive Officer since 2024
PhD in Pharmaceutical Sciences from Kyoto University